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Abstract
P58
IPK is one of the endoplasmic reticulum- (ER-) localised DnaJ (ERdj) proteins which interact with the chaperone BiP, the
mammalian ER ortholog of Hsp70, and are thought to contribute to the specificity and regulation of its diverse functions.
P58
IPK, expression of which is upregulated in response to ER stress, has been suggested to act as a co-chaperone, binding
un- or misfolded proteins and delivering them to BiP. In order to give further insights into the functions of P58
IPK, and the
regulation of BiP by ERdj proteins, we have determined the crystal structure of human P58
IPK to 3.0 A ˚ resolution using a
combination of molecular replacement and single wavelength anomalous diffraction. The structure shows the human P58
IPK
monomer to have a very elongated overall shape. In addition to the conserved J domain, P58
IPK contains nine N-terminal
tetratricopeptide repeat motifs, divided into three subdomains of three motifs each. The J domain is attached to the C-
terminal end via a flexible linker, and the structure shows the conserved Hsp70-binding histidine-proline-aspartate (HPD)
motif to be situated on the very edge of the elongated protein, 100 A ˚ from the putative binding site for unfolded protein
substrates. The residues that comprise the surface surrounding the HPD motif are highly conserved in P58
IPK from other
organisms but more varied between the human ERdj proteins, supporting the view that their regulation of different BiP
functions is facilitated by differences in BiP-binding.
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Introduction
P58
IPK (58-kDa inhibitor of protein kinase) is a member of the
endoplasmic reticulum- (ER-) localised DnaJ family of proteins
(ERdj proteins) which interact with BiP, an important regulator of
the functions of the endoplasmic reticulum (ER) (recently reviewed
by Otero et al. [1]). BiP, the mammalian ER ortholog of Hsp70, is
involved in folding and maturation of nascent proteins as well as
targeting misfolded proteins for degradation and regulating the
unfolded protein response. Like other members of the Hsp70
family, BiP interacts with DnaJ proteins (also known as Hsp40s);
binding of the J domain to the ATPase domain of BiP enhances its
ATPase activity and enables a tighter binding between BiP and its
substrate. In the mammalian ER, there are seven BiP-binding J
domain proteins (ERdj1-7) described to date. These different ERdj
proteins have been suggested to function as co-chaperones, and
are thought to contribute to the specificity and regulation of the
diverse functions of BiP [1]. The ERdj proteins all contain the J
domain, but beyond this they have little or no sequence identity,
and all contain very different functional domains in the remainder
of their sequence. This structural and functional diversity is key to
their emerging roles in regulating the various functions of BiP.
P58
IPK, also known as ERdj6 or DnaJC3, contains the
conserved J domain close to its C-terminus, and a 41 kDa N-
terminal domain comprised of nine tetratricopeptide repeat (TPR)
motifs. P58
IPK has several known interaction partners and, like
many members of the ERdj family, it appears to have quite diverse
functions in the cell; it was initially identified as a cytosolic
inhibitor of PKR (RNA-activated protein kinase) in influenza
infection [2]. During the cellular response to viral infection PKR,
upon activation by dsRNA, phosphorylates the a subunit of the
eukaryotic initiation factor 2 (eIF2a), leading to decreased
synthesis of host and viral proteins. In order to prevent these
events, the virus recruits P58
IPK to inactivate PKR, thereby
allowing viral protein synthesis to continue [2]. Binding of P58
IPK
to PKR is inhibited through interaction with another protein,
P52
rIPK (52-kDa repressor of the inhibitor of protein kinase) [3].
The transcription of P58
IPK was later shown to be induced in
response to ER stress [4]. When unfolded proteins accumulate in
the ER, specific pathways, collectively termed the unfolded protein
response (UPR) (recently reviewed by e.g. Wiseman et al., Ron &
Walter, and Zhang & Kaufman [5–7]), are evoked. This ultimately
leads to reduced import of proteins into the ER and upregulation
of genes encoding ER chaperones and components of the ER
associated degradation pathway. P58
IPK is one of the proteins that
are transcriptionally induced during the UPR and is known to
bind PERK (PKR-like ER kinase), one of the key regulators of the
response, controlling PERK-dependent phosphorylation of eIF2 in
the later stages of the response [4].
While P58
IPK had already been linked to the UPR by its
inhibition of PERK, its direct interaction with BiP came to light
after the cellular localisation of the protein was re-examined by
Rutkowski and co-workers [8]. P58
IPK is now known to contain an
N-terminal ER-localisation signal, and to be found primarily in the
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e22337ER lumen; it is thought that slightly inefficient translocation
explains the small fraction of the protein remaining in the cytosol
[8]. The roles of P58
IPK in the ER lumen and its involvement in
the UPR have been the focus of many recent studies. Its confirmed
involvement with BiP suggested a co-chaperone function, a role
that has been endorsed by recent findings indicating that P58
IPK
can also make a direct interaction with unfolded protein substrates
[9]. A co-chaperone function is further supported by the fact that
P58
IPK deficient cells show a reduced ability to cope with
misfolded proteins [8], as well as the fact that knockout of the
gene encoding P58
IPK in a mouse model causes a mild diabetic
phenotype [10]. Most recently it has been proposed that P58
IPK
binds unfolded protein substrates, stabilises them, and then
subsequently binds BiP and facilitates the transfer of the substrate
to the chaperone [9]. While it looks likely that this is the case,
many questions remain, not least concerning the hand-over of
substrate from P58
IPK to BiP. Recently, the first structure of the
TPR domain of the mouse P58
IPK protein was determined [9].
This identified a putative binding site for unfolded protein, but
could not provide any information on the interactions with BiP
due to the absence of the J domain. Structural information on the
interacting domain of BiP is available [11], but structures of the J
domains of the ERdj proteins, and ultimately of BiP-ERdj
complexes, will be necessary in order to determine the similarities
and differences in their interactions and to understand their roles
in regulating the functions of BiP.
In this study we present the structure of human P58
IPK,
including the BiP-binding J domain. The crystal structure reveals
P58
IPK to be an elongated protein, with the J domain attached to
the very end of the TPR domain via a flexible linker. From the
structure we can identify the probable binding site for BiP based
on the position of the conserved histidine-proline-aspartate (HPD)
motif which is necessary for Hsp40-Hsp70 interactions. This motif
is positioned on the very edge of the elongated protein and at a
distance of 100 A ˚ from the previously suggested site for binding of
unfolded protein substrates. The large distance between the two
binding sites will have implications for the mechanism by which
unfolded protein is passed from the co-chaperone to BiP.
Results and Discussion
Purification and crystallisation
Multiple constructs of the mature P58
IPK, lacking the N-
terminal signal recognition sequence, were initially prepared and
screened for solubility with varied success. No constructs including
the 43 C-terminal amino acid residues, which are predicted to be
unstructured, could be expressed in soluble form. The longest
soluble construct (residues 35–461) therefore consisted of the TPR
domain and the J domain, without these C-terminal residues, and
this was used for crystallisation. Extensive screening for crystalli-
sation conditions was performed using protein both with and
without the N-terminal His-tag that was included in the expression
construct, but crystals were obtained in only a single condition
using protein containing the intact His-tag (crystal form 1). Despite
extensive optimisation and screening of many crystals at the
synchrotron beamline, these native crystals did not diffract beyond
4–5 A ˚. However, selenomethionine-substituted crystals, intended
for phasing purposes, diffracted to a maximum of 3.2 A ˚ and
provided the dataset which was used to solve the structure in space
group P312 using a combination of molecular replacement and
single wavelength anomalous diffraction phasing. Finally, it was
found that using this optimised condition to crystallise native
protein, after enzymatic cleavage of the His-tag, yielded crystals
that looked very similar but diffracted in space-group H32 (crystal
form 2). These crystals provided the dataset used to refine the
structure at 3.0 A ˚. The two crystal forms are very closely related.
Crystal form 1 (P312) has one chain in the asymmetric unit and
crystal form 2 (H32) has three chains. If chain A of crystal form 2 is
superimposed on the single chain in crystal form 1, chains B and C
are shifted only 2–4 A ˚ and 1–2 A ˚, respectively, from symmetry-
generated chains in the other space-group. The crystals have
estimated solvent content of approximately 72% in crystal form 1
and 71% in crystal form 2. Table 1 shows a summary of the
statistics for each of the datasets.
Quality of the electron density maps and models
In both structures, the mainchain density for P58
IPK is
essentially complete and the majority of sidechains are clearly
visible. In both crystal forms, the electron density in the TPR
domain is of particularly high quality for the moderate resolution,
while the density for the J domain is weaker. The linker between
the TPR domain and the J domain (particularly residues 402–408)
and a loop in the J domain (particularly residues 425–428) show
highest flexibility, however even these regions are relatively well
resolved in chain A of crystal form 2, which enabled model
building. The final models of P58
IPK both contain residues 35–
455. The refinement statistics are summarised in Table 2. The
structure in the two crystal forms is very similar, with root mean
square deviation (RMSD) of 0.8 A ˚ (using chain A from crystal
form 2). The three chains in the higher resolution structure of
crystal form 2 show RMSD of 0.4 A ˚ between A and B, 0.5 A ˚
between A and C and 0.7 A ˚ between B and C. In this crystal form,
the density quality is highest, and B-factors lowest, in chain A,
while B and C have weaker density. Due to the high density
quality of chain A, all analysis is based on this molecule unless
stated otherwise. Composite omit maps showing the electron
density corresponding to each of the domains and the linker
between them in this chain are shown in Figure S1.
Overall structure of human P58
IPK
P58
IPK is an entirely a-helical protein with a very elongated
monomer structure, approximately 120 A ˚ long but only 20–50 A ˚
wide (Figure 1). The protein used for crystallisation behaves as a
monomer in gel-filtration chromatography, in agreement with
previously published observations for the TPR domain [9,12].
PISA [13] suggests the oligomeric state to be monomeric in crystal
Table 1. Data collection statistics.
Data set
Crystal form 1,
Se-Met Crystal form 2
Space group P312 H32
Unit cell (A ˚) 124.6, 124.6, 92.22 212.3, 212.3, 283.5
Molecules in asymmetric unit 1 3
Resolution (A ˚) 30.0-3.20 (3.37–3.20) 25.0-3.00 (3.16-3.00)
Rmerge 0.090 (0.602) 0.082 (0.557)
,I./,sI. 8.9 (2.1) 11.5 (2.2)
Completeness (%) 99.9 (100.0) 96.6 (79.2)
Multiplicity 4.6 (4.5) 4.3 (3.7)
Anomalous completeness (%) 99.3 (99.4)
Anomalous multiplicity 2.4 (2.3)
Wilson B-factor (A ˚2) 74.7 67.4
Data in parentheses are for the highest resolution shell.
doi:10.1371/journal.pone.0022337.t001
Structure of Human P58
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crystallographic symmetry, in crystal form 1. However, no
previous data support such a trimeric quarternary structure and
in light of the gel-filtration data it does not seem likely to be
physiologically relevant. The N-terminal TPR domain (residues
35–392) consists of 19 a helices arranged in nine TPR motifs,
motifs of 34 amino acid residues which adopt a helix-turn-helix
arrangement and often pack together to form domains mediating
protein-protein interactions and the assembly of multiprotein
complexes [14,15]. In P58
IPK this part of the protein is further
divided into three subdomains, each containing three TPR motifs.
Subdomain I is composed of helices 1–7 and TPR1-TPR3,
subdomain II is composed of helices 7–13 and TPR4-TPR6, and
subdomain III is composed of helices 13–19 and TPR7-TPR9.
Although the sequence identity between the TPR subdomains is
low, the folds of the three subdomains are similar.
The J domain is composed of residues 393–455. The first three
residues of the J domain (393–395) adopt an extended conforma-
tion, and are followed by a very short helical segment and a long
loop (residues 398–408). This section, which essentially forms a
linker between the TPR domain and the main body of the J
domain, is then followed by two longer anti-parallel helices
(residues 408–421 and 429–448, respectively). After the second
long helix the density gets weaker, indicating flexibility, although
residues 452–454 form another single turn of helix. The last six
residues of the J domain are not visible in the electron density,
despite being present in the crystallised protein. This, together
with our observation that protein constructs including the C-
terminal amino acid residues are not soluble, would appear to
confirm predictions that the extreme C-terminus of P58
IPK
(approximately residues 455–504) is unstructured.
There are two disulfide bonds in the structures of P58
IPK; one
between Cys248 and Cys258 linking helices 12 and 13 and one
between Cys313 and Cys329 linking helices 15 and 16. This is
consistent with P58
IPK’s primary location in the oxidative
environment of the ER. Both disulfides are located in the core
of the protein.
Table 2. Refinement and model building statistics.
Data set
Crystal form 1,
Se-Met Crystal form 2
Refinement statistics
Reflections in working set 12967 44987
Reflections in test set 677 2416
R-factor/R-free 0.244/0.286 0.243/0.291
Number of protein atoms 3429 10259
Average B-factor (including TLS
contribution) (A ˚2)
118.5 107.1
RMSD values from ideal
Bond lengths (A ˚) 0.012 0.008
Bond angles (u) 1.26 1.04
Ramachandran plot
Favoured regions 95.02% 96.58%
Outliers 0.47% 0.32%
doi:10.1371/journal.pone.0022337.t002
Figure 1. Overall structure of human P58
IPK. (A) A cartoon representation of the structure of human P58
IPK, coloured from blue at the N-
terminus to red at the C-terminus. (B) A surface representation of P58
IPK, with the three TPR subdomains and the J domain depicted in blue, green,
yellow and red, respectively.
doi:10.1371/journal.pone.0022337.g001
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A partial structure of mouse P58
IPK was recently published,
containing only the TPR domain (PDB ID: 3IEG) [9]. Despite
very high sequence identity between the two homologues, the
overall structure of the human TPR domain has a significantly
different shape than that of the mouse protein. Superimposing
amino acid residues 35–393 gives an RMSD of 3.7 A ˚ (Figure 2).
This difference is caused primarily by rotations of the long helices
7 and 13 connecting subdomain II to subdomains I and III,
respectively, which bring all three subdomains closer together and
give the human structure a more curved shape.
When solving the human P58
IPK structure, we found that using
the complete mouse TPR domain as search model for molecular
replacement was unsuccessful; a solution could only be found after
removal of the N-terminal half of the mouse structure from the
model. The differences between the human and mouse crystal
structures explain this observation, but also raise the question of
whether the observed differences have any physiological relevance.
It is possible that there could in fact be a structural difference
between the two homologues, although this is unlikely considering
their very high sequence identity. The isolated context of the
mouse TPR domain could also account for the differences
between the two structures; the absence of the J domain could
potentially affect the shape of the TPR domain. A third, and
perhaps more likely, possibility is that the differences arise as an
effect of crystal packing. Each chain in our structure makes similar
crystal packing interactions, and these are indeed different from
those seen in the crystals of the mouse TPR domain. However,
regardless of the reason, the observed differences in structure do
emphasise an inherent flexibility of P58
IPK, which is very likely to
be important for its function. P58
IPK binds multiple interaction
partners, often two or more simultaneously, and the flexibility is
likely to facilitate this.
J domain and BiP binding site
The J domain is the common feature of all proteins in the
Hsp40 family; type I and type II Hsp40s contain additional
conserved domains, while the type III Hsp40-like proteins, such
as P58
IPK, share only the J domain. The structures of J domains
from several different Hsp40s from various organisms have been
solved, and they all contain four alpha helices; one short (I), two
longer (II and III) and another short (IV). Between the second
and third helices lies a conserved histidine-proline-aspartate
(HPD) motif which is required for Hsp70 interaction [16]. Our
structures provide the first structural data on the J domain of
P58
IPK, and confirm the fold to be similar to those of other
Hsp40s. A Dali [17] search using only the J domain reveals the
closest structural homologue to be HscB from Vibrio cholerae (PDB
ID: 3HHO), which aligns with an RMSD of 1.5 A ˚ over 61 amino
acid residues. The structure of the two long helices, and the loop
between them, is very similar to previous J domain structures, but
in P58
IPK the two short helices are barely present, with each
represented by just one turn of a helix (Figure 3A). In the case of
helix I, this is part of the linker connecting the TPR domain and
the J domain, and a shorter helix could contribute to the
flexibility of the protein. Since the protein is known to function
primarily by interactions with other proteins, such as in its
proposed role in passing an unfolded protein to the chaperone
BiP, it is conceivable that a degree of flexibility of the protein
could be beneficial to its function. Helix IV is shorter in P58
IPK
than in previously published J domains, and the subsequent
residues are disordered and not seen in the structure, but it is
possible that the residues missing from the extreme C-terminus,
although predicted themselves to be disordered, could influence
the structure here.
Previous studies have confirmed that the conserved HPD motif
of P58
IPK is important for its specific interaction with Hsp70
proteins, including BiP; point mutations introduced into the motif
resulted in the loss of J domain function, consistent with other
Hsp40-Hsp70 interactions [18,19]. The P58
IPK construct used for
crystallisation includes the complete J domain, and the structure
allows us to examine the area around the HPD motif in detail for
the first time. The structure confirms that this HPD motif (residues
422–424), and therefore the predicted BiP-interaction site, is
located at the start of the loop between the two large helices of the
J domain (helix II and helix III). The motif is positioned at the very
edge of the elongated P58
IPK structure, allowing plenty of space
Figure 2. Comparison between human and mouse P58
IPK TPR domains. A superimposition of the human P58
IPK structure and the previously
published structure of the TPR domain of mouse P58
IPK. Human P58
IPK is coloured from blue at the N-terminus to red at the C-terminus, the TPR
domain of mouse P58
IPK in grey. The structural alignment was based on TPR subdomain II.
doi:10.1371/journal.pone.0022337.g002
Structure of Human P58
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both the aspartate and the histidine are on the surface of the
protein.
Significant evidence accumulated from structural, mutagenesis
and peptide-inhibition studies has shown that the Hsp40-Hsp70
interaction requires helix II of a J domain, the loop between the
second and third helices and, potentially to a lesser extent, helix III
[20–23]. Positively charged residues of helix II have been
particularly strongly implicated, and are thought to interact with
negatively charged residues in the binding cleft of the Hsp70
nucleotide binding domain (NBD) [21,24]. In P58
IPK the region
encompassing the surface of helix II, the loop and the start of helix
III is indeed comprised of a combination of positively charged and
hydrophobic residues, and the charged residues are localised
primarily to helix II, in agreement with previous data. However,
P58
IPK has a lower proportion of charged surface in this area than
most other J domain structures, and those residues that are present
(Lys412, Arg415, and Lys416) are on the N-terminal end of helix
II which is furthest from the HPD motif (Figure 3B). Instead the J
domain of P58
IPK has a higher proportion of hydrophobic surface;
immediately adjacent to the HPD motif is situated a patch of
hydrophobic residues. This hydrophobic patch, which includes
residues Tyr395, Tyr414, Ala418, Leu419, Phe439, Ile440, Ile442,
Ala443, Ala444, and Val448, has approximate dimensions of 12
by 15 A ˚ (Figure 3C). In other J domain structures there is
frequently a hydrophobic patch next to the HPD motif, but its size
and position are not consistent; that seen in the human P58
IPK
structure is amongst the more extensive. Given its position, it is
reasonable to speculate that this hydrophobic patch could be
involved in the interaction between P58
IPK and BiP, and that the
interaction might therefore be more of a hydrophobic, rather than
charged, nature. While the exact binding site on BiP is not known,
there is a conserved arginine residue in the Hsp70 family which
has been previously shown in several cases to interact with the
HPD motif of J domains [22,25]. The equivalent residue in BiP,
Arg197, which has already been implicated in the interaction with
two other mammalian ERdj proteins [26–28], is surrounded by
hydrophobic surface residues in the structure of human BiP. If this
residue does also interact with the J domain of P58
IPK, the BiP
structure would therefore be entirely consistent with our
hypothesis.
Interestingly, the residues surrounding the HPD motif do not all
coincide with those that are best conserved within the human BiP-
binding ERdj family. Each of the positively charged residues on
helix II is conserved in five out of the seven proteins but of the
residues in the hydrophobic patch, only those closest to the HPD
motif are highly conserved; with Phe439 present in all of the seven
ERdj proteins, and Tyr414 and Ala418 present in five (Figure 4A).
This is not completely unexpected; as the interaction partner,
human BiP, is the same for each, it follows that different
interaction characteristics must be conferred by differences in
the J domains. In contrast, the residues surrounding the HPD
motif, as well as the J domains in general, are very highly
conserved between P58
IPK homologues from various organisms
(Figure 4B). Mutagenesis experiments are underway in order to
determine which of these surface residues are directly involved in
the P58
IPK-BiP interaction.
Potential binding sites for other interaction partners
It is known that the varied functions of P58
IPK in the cell require
binding of several very different interaction partners, and it is
therefore of particular interest to analyse the remainder of the
surface of the protein. The solvent-accessible surface of P58
IPK is
approximately 24400 A ˚ 2. A hydrophobic surface analysis
(Figure 5A) shows a major patch of hydrophobic residues lining
a groove close to the N-terminus of the protein. This hydrophobic
patch, which includes residues Leu48, Ala49, Ala50 Leu53,
Leu57, Phe60, Tyr71, Ile72, Tyr74, Tyr75, Ala78, Phe81, Leu82,
Ala83, Met84, Leu94, Leu100, Phe104, Ala106, Leu109 and
Leu114, is approximately 20 by 25 A ˚, covering a large portion of
the surface of TPR subdomain I. This is the same hydrophobic
patch that was also identified in mouse P58
IPK [9]. Despite the
obvious differences in overall conformation between the structure
of human P58
IPK and the previous structure of the mouse TPR
domain, both the shape and the position of the patch are highly
conserved. This would be consistent with an important role in
binding unfolded proteins, as suggested by the authors of the
mouse TPR domain structure. The same authors also suggested
that P58
IPK interacts with unfolded proteins via its TPR domain,
recruits BiP via the J domain and then delivers the substrate to
BiP. The structure of human P58
IPK certainly does not rule out
this theory in any way, but does raise one interesting point. P58
IPK
is a particularly elongated protein and the distance between the
putative unfolded peptide binding site in TPR subdomain I and
the BiP binding site is therefore very large, at approximately
100 A ˚. The mechanism by which P58
IPK would transfer an
unfolded protein substrate to BiP is not yet understood, but given
the conformational difference already seen between the TPR
Figure 3. The J domain of P58
IPK. (A) A cartoon representation of the J domain of P58
IPK. The residues of the HPD motif are shown in stick
representation and coloured by atom type with carbon in grey, oxygen in red, and nitrogen in blue. (B) A surface representation of the J domain,
showing the electrostatic surface potential with positively charged regions in blue and negatively charged regions in red. Positively charged residues
on helix II are labelled. (C) A surface representation of the J domain, with hydrophobic residues in green. Residues contributing to the hydrophobic
patch adjacent to the HPD motif are labelled.
doi:10.1371/journal.pone.0022337.g003
Structure of Human P58
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possible that P58
IPK in the complex could undergo a structural
rearrangement to bring the two sites closer together. It has also
previously been suggested that some Hsp40s could interact
additionally with other regions of their Hsp70 partner, beyond
the classical J domain – NBD interaction [29]. Taking into
account the distance between the J domain and the predicted
binding site for unfolded protein this could be envisaged as a
possibility in this case, however previous studies have indicated
that a P58
IPK construct without the J domain does not interact
with BiP [8].
While the BiP-interaction site can be localised by the conserved
HPD motif, the exact binding sites of P58
IPK’s other interaction
partners are more difficult to predict from current data. The
interaction between P58
IPK and PKR, which inhibits dimerisation
of the kinase [30], has been shown to involve TPR6 [31,32].
Figure 4. Sequence conservation between J domains from the human ERdj proteins and from P58
IPK from different species. (A)
Alignment of sequences of the J domains from the human ERdj proteins. The surface residues mentioned in the text are labelled, using (*) for the
residues of the conserved HPD motif, (#) for residues of the adjacent hydrophobic patch in human P58
IPK, and (1) for positively charged residues on
helix II. Conserved residues are shown with red background, and residue numbering corresponds to human P58
IPK. (B) Sequence alignment of the J
domains from P58
IPK from different species. Labelling is the same as in (A).
doi:10.1371/journal.pone.0022337.g004
Figure 5. The surface of P58
IPK. (A) Surface representations of human P58
IPK, with hydrophobic residues highlighted in green. (B) Electrostatic
surface representations with positively charged regions in blue and negatively charged regions in red.
doi:10.1371/journal.pone.0022337.g005
Structure of Human P58
IPK
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residues of P58
IPK that mediate the interaction remain to be
defined, and surface analysis of TPR6 in our structure does not
reveal any obvious binding sites. The cytosolic regulatory protein
P52
rIPK has been proposed to bind to and inhibit P58
IPK at TPR7
[33]. The surface of TPR7 again does not show any extensive
hydrophobic patches, but this part of the protein has a high
proportion of charged surface (Figure 5B). It has been shown that
P52
rIPK binds to P58
IPK via a charged domain that has limited
homology to the charged domain of Hsp90 [33], and the charged
surface of TPR7 suggests that this interaction could be of an
electrostatic nature. Further experiments will be required in order
to test this hypothesis and indeed to fully characterise the
interactions between P58
IPK and its diverse interaction partners.
However this structure, the first structure of P58
IPK with the J
domain, has provided new insights into the protein, and will now
provide the basis for detailed interaction studies and other
experiments to further characterise the functions of P58
IPK in
the cell and how these functions are brought about by its many
interactions with other proteins.
Materials and Methods
Cloning
The cDNA corresponding to the TPR repeats and the J domain
(residues 35–461) of human P58
IPK was amplified by the
polymerase chain reaction and cloned into pNIC28-Bsa4 by
ligation-independent cloning [34]. The resulting expression
construct contained a hexahistidine tag and a TEV-protease
cleavage site (MHHHHHHSSGVDLGTENLYFQSM) at the N-




IPK was expressed in Escherichia coli
Rosetta (DE3) cells. Cultures in LB medium were incubated with
shaking at 37uCt oO D 600 0.5–0.8, at which point the temperature
was lowered to 18uC and recombinant protein production was
induced by addition of isopropyl b-D-thiogalactopyranoside to a
final concentration of 0.2 mM. The cultures were then grown for
an additional 17–21 h at 18uC before harvest by centrifugation.
Cell pellets were frozen and stored at 220uC until further use.
Selenomethionine-substituted protein was produced by suppres-
sion of methionine biosynthesis using standard methods [35].
Prior to purification, the cell pellets were thawed and
resuspended in 5 ml/g cell weight of lysis buffer (50 mM sodium
phosphate, pH 8.0, 500 mM NaCl, 5 mM imidazole) supplied
with Complete protease inhibitor cocktail (Roche) and lysed by
sonication at 4uC. Cell debris was removed by centrifugation and
the soluble fraction was filtered through double syringe filters
(0.45 mm and 0.22 mm pore size). The protein was purified in
three consecutive steps of chromatography. The cell lysate was
loaded onto a HisTrap HP column (GE Healthcare) and eluted
with increasing imidazole concentration, followed by anion
exchange on a Q HiTrap column (GE Healthcare) against
increasing concentration of NaCl. Size-exclusion chromatography
was performed on a Superdex 200 column (GE Healthcare) using
a gel-filtration buffer consisting of 50 mM Tris-HCl, pH 8.0, and
300 mM NaCl. When appropriate, the hexahistidine tag was
removed by overnight incubation with TEV protease and
separated from P58
IPK by Ni-NTA affinity chromatography.
Samples containing native and selenomethionine-derivative
P58
IPK were dialysed against crystallisation buffer (25 mM Tris,
pH 8.0, 100 mM NaCl, 2 mM DTT), concentrated to 31 and
18 mg/ml, respectively, and used in subsequent crystallisation
experiments. The size of the protein and the incorporation of
selenomethionine were verified by mass spectrometry.
Crystallisation
Initial crystallisation screening was performed by the sitting
drop vapour-diffusion method using standard crystal screens
(Qiagen, Hampton Research, Emerald Biostructures). Suitable
crystallisation conditions were established and optimised for native
and selenomethionine-substituted protein. P58
IPK was crystallised
in two different crystal forms. Crystal form 1 (selenomethionine)
grew at 4uC in drops comprised of 1 ml of well solution and 2 mlo f
protein solution (18 mg/ml). The well solution contained 0.1 M
Tris, pH 8.5, 1.3 M succinic acid and 1% (w/v) PEG MME 2000.
Crystal form 2 (native, without His-tag) grew at 20uC in drops
comprised of 1 ml of well solution and 2 ml of protein solution
(31 mg/ml). The well solution contained 0.1 M HEPES, pH 8.2,
1.4 M succinic acid and 1% (w/v) PEG MME 2000. Crystals
typically began to grow after 1–2 weeks. Prior to data collection,
crystals were cryoprotected using artificial mother liquor contain-
ing 25% glycerol and were flash-frozen in liquid nitrogen.
Data collection and processing
X-ray diffraction data for native and selenomethionine-
substituted P58
IPK crystals were collected at the European
Synchrotron Radiation Facility, Grenoble, France. Anomalous
data were collected from a single selenomethionine-substituted
crystal of crystal form 1 to 3.2 A ˚ resolution on beamline ID23-1,
which is equipped with an ADSC Q315R CCD detector. 120
degrees of data were collected at a wavelength of 0.979 A ˚ using a
1u oscillation angle. Higher resolution native data were collected to
a resolution of 3.0 A ˚ on beamline ID14-1 which is equipped with a
ADSC Q210 CCD detector, using a single crystal of crystal form
2. 73.15 degrees of data were collected at a wavelength of 0.933 A ˚
using a 0.55u oscillation angle. Data were processed using iMosflm
[36] and SCALA from the CCP4 suite [37]. Table 1 shows a
summary of the statistics for each of the datasets.
Phasing, model building and refinement
Phases for crystal form 1 were obtained by a combination of
single wavelength anomalous diffraction and molecular replace-
ment (MR-SAD) using the PHENIX [38] interface to Phaser [39],
with the C-terminal half (residues 203–393) of the TPR domain of
mouse P58
IPK (PDB ID: 3IEG) [9] as the search model. SAD
phasing alone was sufficient to identify seven selenomethionine
sites with a figure of merit (FOM) of 0.53, however MR-SAD was
ultimately used for phasing as it gave significantly better
preliminary electron density maps and facilitated model building.
Electron density maps were improved by density modification in
Parrot [40] and RESOLVE [41]. The N-terminal part of the TPR
domain was built by manually positioning helices using the mouse
structure as a template where possible. After initial refinement of
the TPR domain, the J domain was built manually using a high-
resolution crystal structure of the J domain of the DnaJ homologue
dnj-2 from C.elegans (PDB ID: 2QSA) as a template. The structure
was refined with alternating cycles of restrained refinement in
REFMAC5 [42] v5.5 and manual inspection and model building
in COOT [43]. In the later stages of refinement, atomic
displacement parameters were refined in REFMAC by the TLS
(translation, libration, and screw) method [44]. The structure of
the higher resolution crystal form 2 was determined by molecular
replacement in Phaser, using the structure from crystal form 1 as
the search model. Three molecules were found in the asymmetric
unit. Iterative rounds of model building and refinement were
Structure of Human P58
IPK
PLoS ONE | www.plosone.org 7 July 2011 | Volume 6 | Issue 7 | e22337carried out using COOT and REFMAC5, respectively. Initial
refinement was performed in REFMAC5 v5.5 with medium NCS
restraints and overall B-factor refinement. Later refinement was
performed in REFMAC5 v5.6 with isotropic B-factor refinement.
Atomic displacement parameters were refined in the final stages by
the TLS method with each of the three monomers in the
asymmetric unit treated as a single TLS group. The geometry of
each model was checked using the validation functions of COOT
in addition to final analysis in MolProbity [45], and the fit between
model and data was assessed in SFCHECK [46]. The results from
refinement are summarised in Table 2. Structure alignments were
carried out using the SSM superposition [47] function in COOT.
Calculations of accessible surface area were performed using the
PISA server [13]. The figures were prepared in PyMOL [48].
Composite omit maps were calculated in CNS [49].
Accession numbers
Structure factors and the coordinates of the final models have
been deposited in the Protein Data Bank (http://www.rcsb.org)
with accession numbers 2Y4T and 2Y4U.
Supporting Information
Figure S1 Composite omit maps. Simulated annealing
composite omit maps contoured at 1.0 s showing the electron
density quality in different parts of chain A in the 3.0 A ˚ resolution
structure. (A) The TPR domain. (B) The J domain. (C) The linker
between the TPR domain and the J domain.
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